PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:PRAH
- CUSIP: N/A
- Web: www.prahs.com
Capitalization:- Market Cap: $4.79845 billion
- Outstanding Shares: 62,471,000
Average Prices:- 50 Day Moving Avg: $74.86
- 200 Day Moving Avg: $65.86
- 52 Week Range: $43.41 - $79.98
P/E:- Trailing P/E Ratio: 44.12
- Foreward P/E Ratio: 20.81
- P/E Growth: 1.31
Sales & Book Value:- Annual Revenue: $1.63 billion
- Price / Sales: 2.83
- Book Value: $12.45 per share
- Price / Book: 5.93
Profitability:- EBIDTA: $262.56 million
- Net Margins: 5.85%
- Return on Equity: 21.87%
- Return on Assets: 7.30%
Debt:- Debt-to-Equity Ratio: 1.01%
- Current Ratio: 1.16%
- Quick Ratio: 1.16%
Misc:- Average Volume: 444,205 shs.
- Beta: 0.48
- Short Ratio: 2.21
Frequently Asked Questions for PRA Health Sciences (NASDAQ:PRAH)
What is PRA Health Sciences' stock symbol?
PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."
How were PRA Health Sciences' earnings last quarter?
PRA Health Sciences, Inc. (NASDAQ:PRAH) released its quarterly earnings data on Wednesday, November, 2nd. The company reported $0.64 earnings per share for the quarter, hitting the consensus estimate of $0.64. The company had revenue of $399.80 million for the quarter, compared to analyst estimates of $394.87 million. PRA Health Sciences had a net margin of 5.85% and a return on equity of 21.87%. PRA Health Sciences's revenue for the quarter was up 15.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.52 EPS. View PRA Health Sciences' Earnings History.
Where is PRA Health Sciences' stock going? Where will PRA Health Sciences' stock price be in 2017?
6 analysts have issued 1-year price objectives for PRA Health Sciences' shares. Their predictions range from $63.00 to $90.00. On average, they anticipate PRA Health Sciences' stock price to reach $78.20 in the next twelve months. View Analyst Ratings for PRA Health Sciences.
Are investors shorting PRA Health Sciences?
PRA Health Sciences saw a decrease in short interest in the month of June. As of June 15th, there was short interest totalling 812,245 shares, a decrease of 24.7% from the May 31st total of 1,078,213 shares. Based on an average daily trading volume, of 378,549 shares, the short-interest ratio is presently 2.1 days. Currently, 2.0% of the shares of the company are sold short.
Who are some of PRA Health Sciences' key competitors?
Some companies that are related to PRA Health Sciences include Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), ICON PLC (ICLR), Charles River Laboratories International (CRL), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX) and Sage Therapeutics (SAGE).
Who are PRA Health Sciences' key executives?
PRA Health Sciences' management team includes the folowing people:
- Colin Shannon, Chairman of the Board, President, Chief Executive Officer
- Linda Baddour, Chief Financial Officer, Executive Vice President
- David W. Dockhorn Ph.D., Executive Vice President, Corporate Compliance Officer
- Max C. Lin, Director
- James C. Momtazee, Director
- Ali J. Satvat, Director
- Jeffrey T. Barber, Independent Director
- Linda S. Grais M.D., Independent Director
When did PRA Health Sciences IPO?
(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.
Who owns PRA Health Sciences stock?
PRA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (3.13%), Russell Investments Group Ltd. (1.42%), Harbour Capital Advisors LLC (0.77%), Vaughan Nelson Investment Management L.P. (0.77%), Bellecapital International Ltd. (0.12%) and Meritage Portfolio Management (0.11%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.
Who sold PRA Health Sciences stock? Who is selling PRA Health Sciences stock?
PRA Health Sciences' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Insight Capital Research & Management Inc., Vaughan Nelson Investment Management L.P., Bank of Montreal Can, KAMES CAPITAL plc, NGAM Advisors L.P., Independent Portfolio Consultants Inc. and Meritage Portfolio Management. Company insiders that have sold PRA Health Sciences stock in the last year include Colin Shannon, David W Dockhorn and Linda Baddour. View Insider Buying and Selling for PRA Health Sciences.
Who bought PRA Health Sciences stock? Who is buying PRA Health Sciences stock?
PRA Health Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC, Russell Investments Group Ltd., Bellecapital International Ltd., Legato Capital Management LLC, Parametrica Management Ltd, Aperio Group LLC, Chase Investment Counsel Corp and Strs Ohio. View Insider Buying and Selling for PRA Health Sciences.
How do I buy PRA Health Sciences stock?
Shares of PRA Health Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PRA Health Sciences' stock price today?
One share of PRA Health Sciences stock can currently be purchased for approximately $73.86.
MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for PRA Health Sciences (NASDAQ:PRAH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.83) |
| Consensus Price Target: | $78.20 (5.88% upside) |
Analysts' Ratings History for PRA Health Sciences (NASDAQ:PRAH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/28/2017 | Citigroup Inc. | Reiterated Rating | Buy | $73.00 -> $90.00 | Low |  |
| 6/26/2017 | Bank of America Corporation | Initiated Coverage | Buy | $89.00 | Low | |
| 6/6/2017 | Credit Suisse Group | Reiterated Rating | Outperform | $69.00 -> $76.00 | Low | |
| 6/1/2017 | Jefferies Group LLC | Set Price Target | Buy | $73.00 | Low | |
| 2/27/2017 | Avondale Partners | Upgrade | Underperform -> Market Perform | $63.00 | N/A | |
| 11/4/2016 | KeyCorp | Reiterated Rating | Buy | | N/A | |
| 6/20/2016 | First Analysis | Initiated Coverage | Equal -> Equal Weight | $47.00 | N/A | |
| 3/28/2016 | SunTrust Banks, Inc. | Upgrade | Neutral -> Buy | $47.00 -> $51.00 | N/A | |
| 11/3/2015 | Robert W. Baird | Boost Price Target | Outperform | $47.00 -> $49.00 | N/A | |
| 8/21/2015 | William Blair | Reiterated Rating | Outperform | | N/A | |
(Data available from 7/28/2015 forward)
Earnings History for PRA Health Sciences (NASDAQ:PRAH)Earnings History by Quarter for PRA Health Sciences (NASDAQ PRAH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/25/2017 | Q1 2017 | $0.58 | $0.60 | $426.81 million | $427.08 million | View | N/A | |
| 2/22/2017 | Q4 2016 | $0.64 | $0.71 | $405.04 million | $413.61 million | View | N/A | |
| 11/2/2016 | Q316 | $0.64 | $0.64 | $394.87 million | $399.80 million | View | N/A | |
| 7/28/2016 | Q2 | $0.59 | $0.63 | $381.25 million | $394.20 million | View | Listen | |
| 4/27/2016 | Q116 | $0.53 | $0.55 | $372.21 million | $372.30 million | View | Listen | |
| 2/24/2016 | Q4 | $0.49 | $0.59 | $353.42 million | $428.90 million | View | Listen | |
| 11/2/2015 | Q3 | $0.45 | $0.52 | $346.05 million | $345.10 million | View | Listen | |
| 7/27/2015 | Q215 | $0.40 | $0.47 | $336.74 million | $336.50 million | View | Listen | |
| 5/6/2015 | Q115 | $0.31 | $0.41 | $329.80 million | $332.00 million | View | Listen | |
| 2/18/2015 | Q414 | $0.30 | $0.35 | $323.50 million | $370.00 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for PRA Health Sciences (NASDAQ:PRAH)2017 EPS Consensus Estimate: $3.01
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.57 | $0.66 | $0.62 |
| Q2 2017 | 3 | $0.68 | $0.79 | $0.73 |
| Q3 2017 | 3 | $0.80 | $0.81 | $0.81 |
| Q4 2017 | 3 | $0.77 | $0.93 | $0.86 |
(Data provided by Zacks Investment Research)
Dividend History for PRA Health Sciences (NASDAQ:PRAH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for PRA Health Sciences (NASDAQ:PRAH)Insider Ownership Percentage: 2.10%
Insider Trades by Quarter for PRA Health Sciences (NASDAQ:PRAH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/17/2017 | Linda Baddour | VP | Sell | 196,393 | $63.59 | $12,488,630.87 | |
| 3/28/2017 | Colin Shannon | CEO | Sell | 50,000 | $64.00 | $3,200,000.00 | |
| 3/27/2017 | David W Dockhorn | Insider | Sell | 85,182 | $62.00 | $5,281,284.00 | |
| 2/23/2017 | Colin Shannon | CEO | Sell | 100,000 | $61.50 | $6,150,000.00 | |
| 8/22/2016 | Colin Shannon | CEO | Sell | 113,133 | $51.57 | $5,834,268.81 | |
| 8/15/2016 | Linda Baddour | VP | Sell | 69,380 | $52.00 | $3,607,760.00 | |
| 8/12/2016 | David W. Dockhorn | VP | Sell | 107,257 | $49.00 | $5,255,593.00 | |
| 5/6/2016 | Linda Baddour | CFO | Sell | 92,308 | $46.70 | $4,310,783.60 | |
| 5/6/2016 | Pra Investors L.P. Kkr | Major Shareholder | Sell | 4,907,692 | $46.70 | $229,189,216.40 | |
| 3/8/2016 | Colin Shannon | CEO | Sell | 77,019 | $42.26 | $3,254,822.94 | |
| 3/8/2016 | Linda Baddour | CFO | Sell | 93,000 | $42.26 | $3,930,180.00 | |
| 3/8/2016 | Pra Investors L.P. Kkr | Major Shareholder | Sell | 4,829,981 | $42.26 | $204,114,997.06 | |
(Data available from 1/1/2013 forward)
Headline Trends for PRA Health Sciences (NASDAQ:PRAH)
Latest Headlines for PRA Health Sciences (NASDAQ:PRAH)
| Source: |
|
| Date | Headline |
|---|
 | PRA Health Sciences Set For A Quarterly Earnings Surprise - Again
seekingalpha.com - July 27 at 6:31 AM |
 | PRA Health Sciences to Report 2nd Quarter 2017 Earnings
finance.yahoo.com - July 26 at 6:30 AM |
 | $447.88 Million in Sales Expected for PRA Health Sciences, Inc. (NASDAQ:PRAH) This Quarter
www.americanbankingnews.com - July 19 at 3:02 PM |
| PRA Health Sciences, Inc. (PRAH) Expected to Post Earnings of $0.72 Per Share
www.americanbankingnews.com - July 17 at 11:29 AM |
| PRA Health Sciences, Inc. (PRAH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 11 at 2:32 PM |
| PRA Health Sciences, Inc. (PRAH) Sees Significant Drop in Short Interest
www.americanbankingnews.com - July 1 at 7:10 AM |
| PRA Health Sciences, Inc. (PRAH) Rating Reiterated by Citigroup Inc.
www.americanbankingnews.com - June 28 at 12:40 PM |
| PRA Health Sciences, Inc. (PRAH) Receives New Coverage from Analysts at Bank of America Corporation
www.americanbankingnews.com - June 26 at 12:16 PM |
| $447.60 Million in Sales Expected for PRA Health Sciences, Inc. (PRAH) This Quarter
www.americanbankingnews.com - June 23 at 5:54 PM |
| $0.72 Earnings Per Share Expected for PRA Health Sciences, Inc. (PRAH) This Quarter
www.americanbankingnews.com - June 21 at 7:34 AM |
| PRA Health Sciences and Jumo Announce Partnership
finance.yahoo.com - June 19 at 10:18 AM |
| PRA Health Sciences, Inc. (PRAH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 16 at 1:08 PM |
| Short Interest in PRA Health Sciences, Inc. (PRAH) Drops By 25.6%
www.americanbankingnews.com - June 14 at 7:14 AM |
| PRA Health Sciences' (PRAH) Outperform Rating Reaffirmed at Credit Suisse Group AG
www.americanbankingnews.com - June 6 at 3:38 PM |
| Zacks: Brokerages Expect PRA Health Sciences Inc (PRAH) Will Post Quarterly Sales of $447.6 Million
www.americanbankingnews.com - May 28 at 10:46 AM |
| PRA Health Sciences Inc (PRAH) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 28 at 9:06 AM |
| Analysts Expect PRA Health Sciences Inc (PRAH) Will Announce Earnings of $0.72 Per Share
www.americanbankingnews.com - May 26 at 10:11 AM |
| PRA Health Sciences Named International Clinical Research Company of the Year
finance.yahoo.com - May 22 at 6:28 PM |
| PRA Health Sciences Inc (PRAH) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 22 at 12:24 PM |
| PRA Health Sciences Inc (PRAH) Short Interest Update
www.americanbankingnews.com - May 13 at 8:16 AM |
| Biopharmaceutical Services Stock Continues To Test New Buy Zone
finance.yahoo.com - May 12 at 8:05 PM |
 | Delmar Pharma (DMPI) Formalizes Collaboration with PRA Health (PRAH) for Phase 3 Trial of VAL-083 in GBM
www.streetinsider.com - May 12 at 8:11 AM |
 | PRAH Crosses Above Average Analyst Target
www.nasdaq.com - May 12 at 8:11 AM |
| DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM)
finance.yahoo.com - May 11 at 8:36 AM |
| PRA Health Sciences Announces The Center for Pediatric Clinical Development
finance.yahoo.com - May 4 at 7:31 PM |
| PRA Health Sciences Inc (PRAH) Expected to Announce Quarterly Sales of $447.6 Million
www.americanbankingnews.com - May 4 at 12:00 PM |
| PRA Health Sciences (PRAH) Getting Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - May 2 at 10:02 PM |
| $0.73 Earnings Per Share Expected for PRA Health Sciences Inc (PRAH) This Quarter
www.americanbankingnews.com - May 2 at 8:00 PM |
| PRA Health Sciences Named Clinical Research Company of the Year
finance.yahoo.com - May 2 at 10:09 AM |
| ETFs with exposure to PRA Health Sciences, Inc. : May 1, 2017
finance.yahoo.com - May 1 at 6:33 PM |
| William Blair Analysts Raise Earnings Estimates for PRA Health Sciences Inc (PRAH)
www.americanbankingnews.com - May 1 at 1:44 PM |
| Q3 2017 Earnings Estimate for PRA Health Sciences Inc Issued By KeyCorp (PRAH)
www.americanbankingnews.com - May 1 at 8:54 AM |
| Q2 2017 EPS Estimates for PRA Health Sciences Inc (PRAH) Decreased by Analyst
www.americanbankingnews.com - May 1 at 7:42 AM |
| PRA Health Sciences (PRAH) Getting Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 29 at 4:47 PM |
| PRA Health Sciences Inc (PRAH) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 29 at 1:05 AM |
| FY2017 EPS Estimates for PRA Health Sciences Inc Increased by William Blair (PRAH)
www.americanbankingnews.com - April 28 at 3:48 PM |
| PRA Health Sciences, Inc. :PRAH-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017
finance.yahoo.com - April 28 at 3:18 PM |
| Edited Transcript of PRAH earnings conference call or presentation 26-Apr-17 1:00pm GMT
finance.yahoo.com - April 27 at 10:34 AM |
 | Research Reports Initiation on Medical Research Stocks -- Alere, OpGen, Novadaq Technologies, and PRA Health
www.prnewswire.com - April 26 at 5:59 PM |
| PRA Health Sciences' (PRAH) CEO Colin Shannon on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 5:59 PM |
| PRA Health Sciences (PRAH) Receives Daily Media Impact Rating of 0.56
www.americanbankingnews.com - April 26 at 3:34 PM |
| PRA Health Sciences Inc (PRAH) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - April 25 at 10:06 PM |
| PRA Health Sciences Inc (PRAH) Issues FY17 Earnings Guidance
www.americanbankingnews.com - April 25 at 7:40 PM |
| PRA Health Sciences beats by $0.02, beats on revenue
seekingalpha.com - April 25 at 6:25 PM |
 | PRA Health Sciences, Inc. Reports First Quarter 2017 Results
globenewswire.com - April 25 at 6:25 PM |
 | PRA Health Sciences beats Street 1Q forecasts
marketbeat.com - April 25 at 4:47 PM |
| PRA Health Sciences Inc (PRAH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 25 at 12:33 PM |
| PRA Health Sciences (PRAH) Receives Daily News Sentiment Rating of 0.44
www.americanbankingnews.com - April 23 at 12:58 PM |
| PRA Health Sciences Inc (PRAH) VP Sells $12,488,630.87 in Stock
www.americanbankingnews.com - April 19 at 4:52 PM |
| PRA Health Sciences (PRAH) Earning Very Positive News Coverage, Report Finds
www.americanbankingnews.com - April 19 at 10:27 AM |
PRA Health Sciences (PRAH) Chart for Friday, July, 28, 2017
